滤泡性淋巴瘤的治疗进展  

Therapeutic Progress of Follicular Lymphoma

作　　者：初文慧 高娜 刘增艳[1] 曹曰针 孙大伟 于文征[1] CHU Wenhui;GAO Na;LIU Zengyan;CAO Yuezhen;SUN Dawei;YU Wenzheng(Department of Hematology,Binzhou Medical University Hospital,Binzhou 256603,China;不详)

机构地区：[1]滨州医学院附属医院血液内科,山东滨州256603

出　　处：《中国医学创新》2024年第13期162-167,共6页Medical Innovation of China

摘　　要：滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性B细胞非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),它是一种异质性疾病,其治疗方式多样,包括观察、放疗和全身治疗。但对于多数患者来说,在找到治疗指征之前观察仍然是最常见的治疗方法。早期FL患者的标准治疗方法是放疗,晚期或复发/难治性FL患者可以选择免疫化疗、靶向免疫治疗等。近年来,随着对FL发病机制的深入研究,新的药物和治疗方法也层出不穷,本文对FL的治疗进展做一综述。Follicular lymphoma(FL)is the most common inert B-cell non-Hodgkin lymphoma(NHL).It is a heterogeneous disease,and its treatment methods are diverse,including observation,radiotherapy and systemic treatment.However,for most patients,observation is still the most common treatment method before finding the indications for treatment.The standard treatment for patients with early-stage FL is radiotherapy,while patients with late-stage or relapsed/refractory FL can choose immunochemotherapy,targeted immunotherapy,etc.In recent years,with the in-depth study of the pathogenesis of FL,new drugs and treatment methods are emerging in an endless stream.This article reviews the therapeutic progress of FL.

关 键 词：滤泡性淋巴瘤 免疫化疗 靶向免疫治疗 

分 类 号：R733.1[医药卫生—肿瘤]